News | Cardiovascular Ultrasound | June 20, 2017

BioImage-2 Study to Investigate Atherosclerotic Disease Progression

Follow-up study will use carotid ultrasound to assess natural history of atherosclerotic plaque in original BioImage cohort

BioImage-2 Study to Investigate Atherosclerotic Disease Progression

June 20, 2017 — Mount Sinai Heart and BioImage-2 LLC recently announced the start of the BioImage-2 study investigating the progression of vascular atherosclerotic plaque in patients who previously participated in the BioImage study.

The original BioImage study recruited 7,687 volunteer participants from Humana members in Greater Chicago and Fort Lauderdale, Fla., without known heart or blood vessel disease. The BioImage participants were between the ages of 55 and 80 years of age. A total of 6,104 participants underwent a variety of imaging studies, including a novel method of performing ultrasound of the carotid arteries. The carotid arteries supply blood to the brain and are easily accessible in the neck.

"Today a broad range of options exist for prevention of atherosclerotic vessel disease, which may lead to heart attack and stroke," said Valentin Fuster, M.D., director, Mount Sinai Heart and physician-in-chief, The Mount Sinai Hospital, and principal investigator of the BioImage-2 study.  "If we can identify and characterize subclinical disease early and monitor this over the years, this may one day help us to better identify those who stand to gain most from the intensive preventive therapy options now available."

The original BioImage study was conducted between January 2008 and June 2009, and required that participants make a single visit to a BioImage research center. The study provided important new insights in the presence of atherosclerotic plaque disease in the large arteries and how this information can improve identification of those at risk for heart attack or stroke.

The new BioImage-2 study aims to recruit a minimum of 1,000 former participants of the original BioImage study. Conducted in collaboration with ChenMed, a leading provider of healthcare for seniors, the objective of BioImage-2 is to investigate the natural progression of plaque disease over the approximately nine years since the original BioImage exam.

The new study will help with the development of methods to one day make carotid ultrasound imaging part of routine clinical practice. This novel method of carotid ultrasound may better inform physicians and their patients to allow them to make the best personal health decisions for the prevention of heart attack and stroke.

The BioImage-2 study is made possible through support from Philips Healthcare and the Investigator-Sponsored Study Program of AstraZeneca.

"The BioImage study indicated the potential of ultrasound imaging to better identify those at risk for major cardiovascular events," said Pieter Muntendam, M.D., who is co-principal investigator of the BioImage-2 study and previously led the original BioImage study and the multi-company HRP consortium that funded it. "BioImage-2 will help us develop and test the tools that would put this on a path to use in clinical practice to better tailor preventive therapies."

BioImage-2 study participants will make a single visit to a mobile BioImage-2 research center located at one or more of the dozen Chen Senior Medical Centers serving Medicare beneficiaries in South Florida. 

For more information: www.bioimage-2.com

Related Content

BioCardia Announces 12-Month Results from TRIDENT Trial of Stem Cell Delivery System
News | Stem Cell Therapies| September 26, 2017
BioCardia Inc. recently announced 12-month results from the Phase II TRIDENT clinical trial, conducted by the...
News | Vena Cava Filters| September 26, 2017
September 26, 2017 — The one-year results of the SENTRY...
Treatment of Heart Attack Patients Depends on Cancer History
News | Cardio-oncology| September 26, 2017
Treatment of heart attack patients depends on their history of cancer, according to research published recently in...
CardiAMP Heart Failure Trial Design Presented at Texas Heart Institute Symposium
News | Heart Failure| September 25, 2017
BioCardia Inc. announced the trial design for its pivotal Phase III CardiAMP Heart Failure Trial was presented during...
Biotronik Studies Demonstrate Efficacy of Minimizing Metal Burden in SFA Therapy
News | Stents Bare Metal| September 22, 2017
Physicians demonstrated that reducing metal burden in superficial femoral artery (SFA) therapy could effectively reduce...
Edwards Inspiris Resilia Valve Receives FDA Approval
News | Heart Valve Technology| September 21, 2017
Edwards Lifesciences Corp. recently received U.S. Food and Drug Administration (FDA) approval for its Inspiris Resilia...
MyoKardia Presents Additional Positive Data From Phase 2 PIONEER-HCM Study at HFSA 2017
News | Heart Failure| September 21, 2017
MyoKardia Inc. announced that additional positive data from the first patient cohort of its Phase 2 PIONEER-HCM study...
DISRUPT BTK Study Shows Positive Results With Lithoplasty in Calcified Lesions Below the Knee
News | Peripheral Artery Disease (PAD)| September 20, 2017
Shockwave Medical reported positive results from the DISRUPT BTK Study, which were presented at the annual...
Corindus Announces First Patient Enrolled in PRECISION GRX Registry
News | Robotic Systems| September 18, 2017
September 18, 2017 — Corindus Vascular Robotics Inc.
Two-Year ILLUMENATE Trial Data Demonstrate Efficacy of Stellarex Drug-Coated Balloon
News | Drug-Eluting Balloons| September 18, 2017
Philips announced the two-year results from the ILLUMENATE European randomized clinical trial (EU RCT) demonstrating...
Overlay Init